Keryx Biopharmaceuticals, Inc. (KERX) Tops Q4 EPS by 2c

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported Q4 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Keryx Biopharmaceuticals, Inc. (KERX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Super Micro Computer (SMCI) Falls 6%
• BancFirst Corp. (BANF) Tops Q1 EPS by 11c
• American Express (AXP) down despite beating Q1 estimates on top and bottom lines